The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients.
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Seagen; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Incuron (Inst); Ipsen (Inst); Loxo (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst)
 
Chandra Prakash Belani
Consulting or Advisory Role - Genentech/Roche; Janssen; Takeda
Research Funding - EMD Serono (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Janssen; Takeda
 
George R. Simon
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Lilly; MD Anderson Physician’s Network; Merck Serono; Takeda
Speakers' Bureau - AstraZeneca; Celgene; DAVA Pharmaceuticals; Nexus Pharmaceuticals Inc; OncLive
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Celgene; Genentech/Roche; Lilly; Merck Serono
 
Heman Chao
Employment - Helix BioPharma; Helix BioPharma (I)
Leadership - Helix BioPharma
Stock and Other Ownership Interests - Helix BioPharma
Patents, Royalties, Other Intellectual Property - Helix BioPharma; Helix BioPharma (Inst)
Travel, Accommodations, Expenses - Helix BioPharma
Other Relationship - Helix Immuno-Oncology
 
Sarina Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)